Telomir Pharms Financials
This page shows Telomir Pharms (TELO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Stronger FY2025 liquidity came from fresh financing, while the expense mix shifted from R&D toward overhead.
Between FY2024 and FY2025, operating cash burn improved from-$5.1M to-$3.7M , showing some moderation in cash use. Yet the balance-sheet upgrade came from financing cash flow of$9.7M , accompanied by shares outstanding rising to 34.4M, which means the stronger cash position was purchased with new capital rather than created by the underlying business.
By FY2025, SG&A reached
The liquidity profile changed sharply, moving from a working-capital squeeze to ample near-term coverage after repeated external funding. By FY2025, cash exceeded total liabilities at
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Telomir Pharms's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Telomir Pharms carries a low D/E ratio of 0.24, meaning only $0.24 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 97/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 5.14, Telomir Pharms holds $5.14 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
Telomir Pharms generates a -176.1% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100.
Telomir Pharms passes 2 of 9 financial strength tests. 1 of 3 profitability signals pass, 1 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, Telomir Pharms generates $0.35 in operating cash flow (-$3.7M OCF vs -$10.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Telomir Pharms reported -$10.4M in net income in fiscal year 2025.
Telomir Pharms earned $-0.33 per diluted share (EPS) in fiscal year 2025. This represents an increase of 41.1% from the prior year.
Cash & Balance Sheet
Telomir Pharms held $7.3M in cash against $0 in long-term debt as of fiscal year 2025.
Telomir Pharms had 34M shares outstanding in fiscal year 2025. This represents an increase of 15.5% from the prior year.
Margins & Returns
Telomir Pharms's ROE was -176.1% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.
Capital Allocation
Telomir Pharms invested $2.4M in research and development in fiscal year 2025. This represents an increase of 9.0% from the prior year.
TELO Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $468K | N/A | $760K+1673.0% | $43K-87.3% | $337K | N/A | $627K+5.5% | $595K |
| SG&A Expenses | $574K | N/A | $387K | N/A | $1.9M | N/A | N/A | $880K |
| Operating Income | N/A | N/A | N/A | N/A | $2.2M | N/A | N/A | N/A |
| Interest Expense | $1K | N/A | N/A | $1K+2817.4% | $46 | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$991K | N/A | -$1.1M | N/A | -$2.2M | N/A | N/A | -$1.4M |
| EPS (Diluted) | $-0.03 | N/A | $-0.03-117.6% | $0.17+342.9% | $-0.07 | N/A | $-0.20-500.0% | $0.05 |
TELO Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $5.8M-21.1% | $7.3M-0.8% | $7.4M+792.2% | $830K+68.9% | $491K-62.9% | $1.3M+27.1% | $1.0M-50.4% | $2.1M |
| Current Assets | $5.8M-21.1% | $7.3M-0.8% | $7.4M+792.2% | $830K+68.9% | $491K-62.9% | $1.3M+27.1% | $1.0M-50.4% | $2.1M |
| Cash & Equivalents | $5.6M-23.7% | $7.3M-0.6% | $7.3M+871.6% | $754K+87.2% | $403K-68.2% | $1.3M+51.7% | $835K-55.7% | $1.9M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $827K-42.1% | $1.4M+237.7% | $423K+21.4% | $348K-46.6% | $652K-4.2% | $681K+13.5% | $600K+12.3% | $534K |
| Current Liabilities | $827K-42.1% | $1.4M+237.7% | $423K+21.4% | $348K-46.6% | $652K-4.2% | $681K+13.5% | $600K+12.3% | $534K |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $5.0M-16.1% | $5.9M-15.3% | $7.0M+1350.3% | $481K+398.7% | -$161K-125.1% | $643K+45.5% | $442K-72.8% | $1.6M |
| Retained Earnings | -$42.0M-2.4% | -$41.0M-5.3% | -$38.9M-2.9% | -$37.8M-15.5% | -$32.8M-7.1% | -$30.6M-10.5% | -$27.7M-27.2% | -$21.8M |
TELO Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.8M-47.6% | -$1.2M-29.6% | -$927K-33.1% | -$696K+19.3% | -$863K-42.5% | -$606K+39.6% | -$1.0M+34.2% | -$1.5M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | $47K-95.9% | $1.2M-84.6% | $7.5M | N/A | N/A | $1.0M+2311.3% | -$47K-135.4% | $132K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
TELO Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -20.0% | N/A | -15.8% | N/A | N/A | N/A | N/A | -85.3% |
| Return on Assets | -17.1% | N/A | -14.9% | N/A | -443.8% | N/A | N/A | -66.1% |
| Current Ratio | 7.00+1.9 | 5.14-12.4 | 17.51+15.1 | 2.38+1.6 | 0.75-1.2 | 1.94+0.2 | 1.74-2.2 | 3.93 |
| Debt-to-Equity | 0.17-0.1 | 0.24+0.2 | 0.06-0.7 | 0.72+4.8 | -4.05-5.1 | 1.06-0.3 | 1.36+1.0 | 0.33 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Telomir Pharms profitable?
No, Telomir Pharms (TELO) reported a net income of -$10.4M in fiscal year 2025.
What is Telomir Pharms's return on equity (ROE)?
Telomir Pharms (TELO) has a return on equity of -176.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Telomir Pharms's operating cash flow?
Telomir Pharms (TELO) generated -$3.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Telomir Pharms's total assets?
Telomir Pharms (TELO) had $7.3M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Telomir Pharms spend on research and development?
Telomir Pharms (TELO) invested $2.4M in research and development during fiscal year 2025.
What is Telomir Pharms's current ratio?
Telomir Pharms (TELO) had a current ratio of 5.14 as of fiscal year 2025, which is generally considered healthy.
What is Telomir Pharms's debt-to-equity ratio?
Telomir Pharms (TELO) had a debt-to-equity ratio of 0.24 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Telomir Pharms's return on assets (ROA)?
Telomir Pharms (TELO) had a return on assets of -141.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Telomir Pharms's cash runway?
Based on fiscal year 2025 data, Telomir Pharms (TELO) had $7.3M in cash against an annual operating cash burn of $3.7M. This gives an estimated cash runway of approximately 24 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Telomir Pharms's Piotroski F-Score?
Telomir Pharms (TELO) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Telomir Pharms's earnings high quality?
Telomir Pharms (TELO) has an earnings quality ratio of 0.35x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Telomir Pharms?
Telomir Pharms (TELO) scores 33 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.